• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture - Product Image

United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

  • ID: 2368694
  • December 2012
  • Region: United Kingdom, Great Britain
  • 309 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott Laboratories
  • Atlas Medical
  • bioMerieux S.A.
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • MORE

United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

Our new report, “United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the United Kingdom In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology, Microbiology Culture and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, READ MORE >

FEATURED COMPANIES

  • Abbott Laboratories
  • Atlas Medical
  • bioMerieux S.A.
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 In Vitro Diagnostics In United Kingdom
3.1 In Vitro Diagnostics, Market Segmentation
3.2 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018
3.3 In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2011
3.4 In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011
3.5 In Vitro Diagnostics, United Kingdom, Company Share (2010-2011)
4 Clinical Chemistry In United Kingdom
4.1 Clinical Chemistry, Market Segmentation
4.2 Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2011
4.3 Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011
4.4 Clinical Chemistry Overall Revenue, (2004-2018)
4.5 Clinical Chemistry Distribution Share (2010-2011)
4.6 Clinical Chemistry, United Kingdom, Company Share (2010-2011)
5 Genetic Testing In United Kingdom
5.1 Genetic Testing, Market Segmentation
5.2 Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2011
5.3 Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011
5.4 Genetic Testing Overall Revenue, (2004-2018)
5.5 Genetic Testing Distribution Share (2010-2011)
5.6 Genetic Testing, United Kingdom, Company Share (2010-2011)
6 Haematology In United Kingdom
6.1 Haematology Market, Market Segmentation
6.2 Haematology Market, United Kingdom, Revenue Mix ($m), 2011
6.3 Haematology Market, United Kingdom, Segment Contribution (%), 2011
6.4 Haematology Overall Revenue, (2004-2018)
6.5 Haematology Distribution Share (2010-2011)
6.6 Haematology, United Kingdom, Company Share (2010-2011)
7 Histology And Cytology In United Kingdom
7.1 Histology and Cytology Market, Market Segmentation
7.2 Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2011
7.3 Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011
7.4 Histology And Cytology Overall Revenue, (2004-2018)
7.5 Histology And Cytology Distribution Share (2010-2011)
7.6 Histology And Cytology, United Kingdom, Company Share (2010-2011)
8 Immuno Chemistry In United Kingdom
8.1 Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2011
8.2 Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011
8.3 Immuno Chemistry Overall Revenue, (2004-2018)
8.4 Immuno Chemistry Distribution Share (2010-2011)
8.5 Immuno Chemistry, United Kingdom, Company Share (2010-2011)
9 Infectious Immunology In United Kingdom
9.1 Infectious Immunology, Market Segmentation
9.2 Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2011
9.3 Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011
9.4 Infectious Immunology Overall Revenue, (2004-2018)
9.5 Infectious Immunology Distribution Share (2010-2011)
9.6 Infectious Immunology, United Kingdom, Company Share (2010-2011)
10 Microbiology Culture In United Kingdom
10.1 Microbiology Culture, Market Segmentation
10.2 Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2011
10.3 Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011
10.4 Microbiology Culture Overall Revenue, (2004-2018)
10.5 Microbiology Culture Distribution Share (2010-2011)
10.6 Microbiology Culture, United Kingdom, Company Share (2010-2011)
11 Overview of Key Companies in United Kingdom In Vitro Diagnostics Market
11.1 Siemens Healthcare
11.2 F. Hoffmann-La Roche Ltd.
11.3 Abbott Laboratories
11.4 Beckman Coulter, Inc.
11.5 Sysmex Corporation
11.6 bioMerieux S.A.
11.7 Ortho-Clinical Diagnostics Inc.
11.8 Bio-Rad Laboratories, Inc.
11.9 Becton, Dickinson and Company
11.10 Alere Inc.
11.11 Phadia AB
11.12 Mindray Medical International Limited
11.13 Qiagen N.V.
11.14 DiaSorin S.p.A
11.15 ELITech Group
11.16 PerkinElmer, Inc.
11.17 Thermo Fisher Scientific Inc.
11.18 Atlas Medical
11.19 Gen-Probe Incorporated
11.20 Horiba, Ltd.
11.21 Diagnostica Stago, Inc.
11.22 Life Technologies Corporation
11.23 Hologic, Inc.
12 In Vitro Diagnostics Market Pipeline Products
12.1 Clinical Chemisty Market Pipeline Products
12.2 Immuno Chemistry Market Pipeline Products
12.3 Haematology Market Pipeline Products
12.4 Infectious Immunology Market Pipeline Products
12.5 Microbiology Culture Market Pipeline Products
12.6 Histology And Cytology Market Pipeline Products
12.7 Genetic Testing Market Pipeline Products
13 Financial Deals Landscape
13.1 Acquisition
13.2 Partnerships
14 Recent Developments
14.1 Strategy And Business Planning
14.2 Government and Public Interest
14.3 Product News
15 Appendix
15.1 Definitions of Markets Covered in the Report
15.2 Research Methodology
15.3 Secondary Research
15.4 Primary Research
15.5 Models
15.6 Forecasts
15.7 Expert Panels
15.8 Consulting
15.9 Currency Conversion
15.10 Contact Us
15.11 Disclaimer

1.1 List of Tables
Table 1: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018
Table 2: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011
Table 3: In Vitro Diagnostics Market, United Kingdom, Cross-Category Analysis, 2004-2018
Table 4: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Table 5: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Table 6: In Vitro Diagnostics, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 7: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011
Table 8: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 9: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 10: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 11: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 12: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 13: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 14: Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 15: Clinical Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 16: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011
Table 17: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 18: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 19: Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 20: Genetic Testing, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 21: Haematology Market, United Kingdom, Segment Contribution (%), 2011
Table 22: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 23: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 24: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 25: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 26: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 27: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 28: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 29: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 30: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 31: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 32: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 33: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 34: Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 35: Haematology, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 36: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011
Table 37: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 38: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 39: Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 40: Histology And Cytology, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 41: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011
Table 42: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 43: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 44: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 45: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 46: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 47: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 48: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 49: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 50: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 51: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 52: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 53: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 54: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 55: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 56: Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 57: Immuno Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 58: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011
Table 59: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 60: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 61: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 62: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 63: Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 64: Infectious Immunology, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 65: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011
Table 66: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 67: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 68: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 69: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 70: Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 71: Microbiology Culture, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 72: Clinical Chemisty Market Pipeline Products
Table 73: Immuno Chemistry Market Pipeline Products
Table 74: Haematology Market Pipeline Products
Table 75: Infectious Immunology Market Pipeline Products
Table 76: Microbiology Culture Market Pipeline Products
Table 77: Histology And Cytology Market Pipeline Products
Table 78: Genetic Testing Market Pipeline Products
Table 79: Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions
Table 80: Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes
Table 81: Abingdon Health Acquires 80% Stake In Forsite Diagnostics
Table 82: Abingdon Health To Acquire 50.1% Stake In Molecular Vision From Imperial Innovations Group
Table 83: Quintiles Acquires Minority Stake In Oxford Cancer Biomarkers For $5 Million
Table 84: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology
Table 85: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery
Table 86: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System
Table 87: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ
Table 88: BioDot Enters Into Co-Marketing Agreement With JOT Automation
Table 89: AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies
Table 90: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays
Table 91: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions
Table 92: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test
Table 93: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
Table 94: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica
Table 95: CML HealthCare Enters Into Agreement With MaRS Innovation
Table 96: Akrivis Technologies Enters Into Co-Development Agreement With United States Biological
Table 97: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test
Table 98: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products
Table 99: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina
Table 100: Dolomite Centre Enters Into Licensing Agreement With Japan Science and Technology Agency For Microdroplet Generation Technology
Table 101: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test
Table 102: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics
Table 103: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center
Table 104: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor
Table 105: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International
Table 106: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
Table 107: Lab21 Enters Into Co-Development Agreement With Pharma Company
Table 108: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
Table 109: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis
Table 110: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test
Table 111: KineMed Enters Into Co-Development Agreement With GlaxoSmithKline
Table 112: One Lambda Enters Into Co-Marketing Agreement With CellTrend
Table 113: GE Healthcare Enters Into Co-Development Agreement With Commonwealth Scientific and Industrial Research
Table 114: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker
Table 115: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems
Table 116: Biocartis Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Philips Research Europe For Oncology Diagnostics
Table 117: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker
Table 118: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology
Table 119: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA
Table 120: Opko Health Enters Into Licensing Agreement With International Health Technology For Prostate Cancer Biomarker Panel
Table 121: Dolomite Centre Enters Into Co-Development Agreement With LioniX
Table 122: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit
Table 123: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo
Table 124: Novo Nordisk Enters Into Co-Development Agreement With Oxford University
Table 125: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology
Table 126: LipoScience Enters Into Licensing Agreement With Cleveland Clinic
Table 127: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System
Table 128: NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers
Table 129: LAB21 Enters Into Co-Development Agreement With IVD Company For Aspergillus Molecular Assay
Table 130: Randox Labs Enters Into Licensing Agreement With Proteome Sciences For Stroke Biomarker
Table 131: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX
Table 132: A-STAR Enters Into Co-Development Agreement With QuantuMDx Group
Table 133: DiaGenic Enters Into Co-Development Agreement With GE Healthcare
Table 134: DNA Electronics Enters Into Licensing Agreement With Gene Onyx For Genalysis Technology
Table 135: Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline
Table 136: ANGLE Enters Into Co-Development Agreement With Paterson Institute for Cancer Research
Table 137: Yissum Research Development Company Enters Into Licensing Agreement With BioConnections For Commercialization Of Kits
Table 138: Oxford Gene Technology Enters Into Licensing Agreement With Oslo University Hospital And University of Oslo
Table 139: VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer
Table 140: Horizon Diagnostics Enters Into Licensing Agreement With UK NEQAS
Table 141: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis
Table 142: Abbott Labs Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals
Table 143: Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation
Figure 2: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018
Figure 3: In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2011
Figure 4: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011
Figure 5: In Vitro Diagnostics Market, United Kingdom, Cross-Category Analysis, 2004-2018
Figure 6: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Figure 7: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Figure 8: In Vitro Diagnostics, United Kingdom, Company Share (%), 2011
Figure 9: Clinical Chemistry, Market Segmentation
Figure 10: Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2011
Figure 11: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011
Figure 12: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 13: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 14: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 15: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 16: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 17: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 18: Clinical Chemistry, United Kingdom, Company Share (%), 2011
Figure 19: Genetic Testing, Market Segmentation
Figure 20: Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2011
Figure 21: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011
Figure 22: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 23: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 24: Genetic Testing, United Kingdom, Company Share (%), 2011
Figure 25: Haematology Market, Market Segmentation
Figure 26: Haematology Market, United Kingdom, Revenue Mix ($m), 2011
Figure 27: Haematology Market, United Kingdom, Segment Contribution (%), 2011
Figure 28: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 29: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 30: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 31: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 32: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 33: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 34: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 35: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 36: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 37: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 38: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 39: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 40: Haematology, United Kingdom, Company Share (%), 2011
Figure 41: Histology and Cytology Market, Market Segmentation
Figure 42: Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2011
Figure 43: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011
Figure 44: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 45: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 46: Histology And Cytology, United Kingdom, Company Share (%), 2011
Figure 47: Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2011
Figure 48: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011
Figure 49: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 50: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 51: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 52: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 53: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 54: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 55: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 56: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 57: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 58: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 59: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 60: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 61: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 62: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 63: Immuno Chemistry, United Kingdom, Company Share (%), 2011
Figure 64: Infectious Immunology, Market Segmentation
Figure 65: Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2011
Figure 66: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011
Figure 67: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 68: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 69: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 70: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 71: Infectious Immunology, United Kingdom, Company Share (%), 2011
Figure 72: Microbiology Culture, Market Segmentation
Figure 73: Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2011
Figure 74: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011
Figure 75: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 76: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 77: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 78: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 79: Microbiology Culture, United Kingdom, Company Share (%), 2011
Figure 80: Siemens Healthcare, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2011
Figure 81: F. Hoffmann-La Roche Ltd., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2011
Figure 82: Abbott Laboratories, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2011
Figure 83: Beckman Coulter, Inc., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2011
Figure 84: Sysmex Corporation, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2011
Figure 85: bioMerieux S.A., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2011

Siemens Healthcare
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Beckman Coulter, Inc.
Sysmex Corporation
bioMerieux S.A.
Ortho-Clinical Diagnostics Inc.
Bio-Rad Laboratories, Inc.
Becton, Dickinson and Company
Alere Inc.
Phadia AB
Mindray Medical International Limited
Qiagen N.V.
DiaSorin S.p.A
ELITech Group
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Atlas Medical
Gen-Probe Incorporated
Horiba, Ltd.
Diagnostica Stago, Inc.
Life Technologies Corporation
Hologic, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos